344 related articles for article (PubMed ID: 34744710)
1. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China.
Sun KX; Cui B; Cao SS; Huang QX; Xia RY; Wang WJ; Wang JW; Yu F; Ding Y
Front Pharmacol; 2021; 12():716224. PubMed ID: 34744710
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
Bamber L; Muston D; McLeod E; Guillermin A; Lowin J; Patel R
Thromb J; 2015; 13():20. PubMed ID: 26074735
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Yan X; Gu X; Xu Z; Lin H; Wu B
Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
[TBL] [Abstract][Full Text] [Related]
10. Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation.
Al Saleh AS; Berrigan P; Anderson D; Shivakumar S
Can J Hosp Pharm; 2017; 70(3):188-199. PubMed ID: 28680172
[TBL] [Abstract][Full Text] [Related]
11. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
12. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
Connell NT; Abel GA; Connors JM
Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ
J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
Li A; Carlson JJ; Kuderer NM; Schaefer JK; Li S; Garcia DA; Khorana AA; Carrier M; Lyman GH
Cancer; 2020 Apr; 126(8):1736-1748. PubMed ID: 31999844
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.
Yan X; Gu X; Zhou L; Lin H; Wu B
Clin Drug Investig; 2016 Dec; 36(12):1001-1010. PubMed ID: 27581246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]